Update on prostaglandin analogs

Current Opinion in Ophthalmology

Volumn 14, Issue 2, 2003, Pages 65-69

  Hylton, Camille ^a   Robin, Alan L ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Bimatoprost; Glaucoma; Hypotensive lipids; Intraocular pressure; Latanoprost; Ocular hypertension; Prostamides; Travoprost

Indexed keywords

ANTIGLAUCOMA AGENT; BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL MALEATE; MATRIX METALLOPROTEINASE; PRODRUG; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TIMOLOL MALEATE; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

CHOROID DETACHMENT; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTAINER; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STORAGE; DRUG TOLERABILITY; ERYTHEMA; EYE BLOOD FLOW; EYELID DISEASE; FLU LIKE SYNDROME; GLAUCOMA; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPERTRICHOSIS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; MUSCLE HYPOTONIA; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; PRIORITY JOURNAL; PRURITUS; RETINA MACULA CYSTOID EDEMA; REVIEW; SCLERA; SENSORY DYSFUNCTION; SIDE EFFECT; STORAGE TEMPERATURE; SYSTEMIC DISEASE; TOPICAL TREATMENT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UVEA;

ADMINISTRATION, TOPICAL; AMIDES; CLOPROSTENOL; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; OCULAR HYPERTENSION; PROSTAGLANDINS; PROSTAGLANDINS F, SYNTHETIC; SAFETY;

EID: 0038239627     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200304000-00001     Document Type: Review

References (48)

1. Shaya FT, Mullins CD, Wong W, et al.: Discontinuation rates of topical glaucoma medications in a managed care population. Am J Managed Care 2002, 8(10 suppl):S271-S277.
2. Spooner JJ, Bullano MF, Ikeda LI, et al.: Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Managed Care 2002, 8(10 suppl):S262-S270.
3. Dasgupta S, Oates V, Bookhart BK, et al.: Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Managed Care 2002, 8(10 suppl):S255-S261.
4. Camras CB, Alma A, Watson P, et al.: Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanaprost Study Group. Ophthalmology 1996, 103:1916-1924.
5. Alm A: Comparative phase III clinical trial of latanoprost and timolol in patients with elevated intraocular pressure. Adv Prostaglandin Thromboxane Leukot Res 1995, 23:527-532.
6. Watson P, Stjernschantz J: A six-month randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanprost Study Group. Ophthalmology 1996, 103:127-137.
7. Azuma I, Masuda K, Kitazawa K: Double-masked, comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open angle glaucoma or ocular hypertension. Jpn J Ophthalmology 1993, 37:514-525.
8. Ishikawa H, Yoshitomi T, Mashimo K, et al.: Pharmacological effects of latanoprost, prostaglandin E2, and F2alpha on isolated rabbit ciliary artery. Graefes Arch Clin Exp Ophthalmol 2002, 240:120-125.
9. Ishii K, Tomidokoro A, Nagahara M, et al.: Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest Opthalmol Vis Sci 2001, 42:2957-2963.
10. Tamaki Y, Nagahara M, Araie M, et al.: Topical latanoprost and the optic nerve head and retinal circulation in humans. J Ocul Pharmacol Ther 2001, 17:403-411.
11. Georgeopoulos Gt, Diestekhorst M, fisher R, et al.: The short-term effect of intraocular pressure and pulsatile ocular blood flow. Acta Ophthalmol Scand 2002, 80:54-58.
12. Ritch R, Ishikawa H, Rothman R, et al.: The efficacy of latanoprost is independent of the width of the ciliary body face. J Glaucoma 2002, 11:239-243.
13. Weinreb RN, Lindsey JD: Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 2002;43(3):716-22.
14. Kashiwagi K, Kanai N, Tsuchida T, et al. Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2) induction, affinity to prostaglandin transporter, and intraocular metabolism. Exp Eye Res 2002, 74:41-49.
15. Larsson LL: Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers: a randomized, double-masked, placebo, controlled, cross-over single center study. Acta Ophthalmol Scand 2001, 79:567-571.
16. Higgenbotham EJ, Feldman R, Stiles M, Dubiner H: Latanoprost and timolo compination therapy vs monotherapy: one year randomized trial. Arch Ophthalmol 2002, 120:915-922.
17. Calissendorff B, Sjoquist B, Hogberg G, et al.: Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared with monotherapy. J Ocul Pharmacol Ther 2002, 18:127-131.
18. Konstas AG, Nakos E, Tersis I, et al.: A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002, 133:753-757.
19. O'Conner DJ, Martone JF, Mead A: Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Opthalmol 2002, 133:836-837.
20. Herdon LW, Asrani SG, Williams GH, et al.: Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost. Arch Ophthalmol 2002, 120:847-849.
21. Saito M, Takano R, Shirato S: Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am J Ophthalmol 2001, 132:485-489.
22. Mansberger SL, Passo MS, Schalock PI, et al.: Predictive value of a 1-day, 1-eye trial on the 1-month ocular hypotensive response of latanoprost 0.005%. Am J Ophthalmol 2001, 132:869-871.
23. VanDenburgh AM, Laibowitz RA, Felix C: A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure. Invest Ophthalmol Vis Sci 1990, 40:S830.
24. Sherwood M, Brandt J, et al.: Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001, 45(suppl 4):S361-S380.
25. DuBiner H, Cooke D, Dirks M, et al.: Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001, 45(suppl 4):S353-S360.
26. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol 2001, 45(suppl 4):S347-S351.
27. Woodward DF, Tang-Liu DD-S, Madhu C, et al.: Prostaglandin F2α (PGF2α) l-ethanolamide: a pharmacologically unique local hormone biosynthesized from anadamide. 11th International Conference on Advances in Prostaglandin and Leukotriene Research 2000, p.27.
28. Woodward DF, Krauss P, Chen J et al.: The Pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 2001, 45(suppl 4):S337-S345.
29. Maxey KM, Johnson JL, LaBrecque J: The Hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 2002, 47(suppl 1):S34-S40. This key article clarifies the mechanism of action of bimatoprost via investigation of its in vitro metabolism in human and bovine corneal tissue.
30. Easthope SE, Perry CM: Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002, 19:231-248.
31. Hellberg MR, Sallee VL, McLaughlin MA, et al.: Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001, 17:421-432.
32. Netland PA, Landry T, Sullivan EK, et al.: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001, 132:472-484. This article suggests that race may account for differences in response to therapy with travoprost compared with latanoprost or timolol.
33. Fellman RL, Sullivan EK, Ratliff M: Comparison of travoprost 0.0015% and 0.004% with Timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multi-center trial. Ophthalmology 2002, 109:998-1008.
34. Orengo-Nania S, Landry T, Von Tress M, et al.: Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001, 132:860-868.
35. Aung T, Chew PT, Oen FT, et al.: Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure. Br J Ophthalmol 2002, 86:75-79.
36. Teus MA, Arranz-Marquez E, Lucea-Suescun P: Incidence of iris color change in latanoprost treated eyes. Br J Ophthalmol 2002, 86:1085-1088.
37. Kobayashi H, Kobayashi K, Okinami S. A comparison of intraocular pressure-lowering effect of prostaglandin F2-alpha analogues, latanoprost, and unoprostone isopropyl. J Glaucoma 2001, 10:487-492.
38. Marques Pereira ML, Katze LJ: Choroidal detachment after the use of topical latanoprost. Am J Ophthalmol 2001, 132:928-929.
39. Tsai JC, Sivak-Callcott JA, Haik BG, et al.: Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J Glaucoma 2001, 10:411-413.
40. Chiba T, Kashiwagi K, Kogure S, et al.: Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma 2001, 10:406-410.
41. Wand M, Shields BM: Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol 2002, 133:393-397.
42. Wand M, Gaudio AR: Cystoid macular edema associated with ocular hypotensive lipids. Am J Ophthalmol 2002, 133:403-405.
43. Gandolfi S, Simmons ST, Sturm R, et al.: Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001, 18:110-121.
44. Novack GD, O'Donnell MJ, Molloy DW: New medications in the geriatric population: efficacy and safety. J Am Geriatr Soc 2002, 50:956-962.
45. Miyake K, Ota I, Maekubo K, et al.: Latanoprost accelerates the disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakia. Arch Ophthalmol 1999, 117:34-40.
46. Latanoprost (Xalatan 0.005%) [package insert]. Peapack, NJ: Pharmacia.
47. Bimatoprost (Lumigan 0.03%) [package insert]. Irvine, CA): Allergan.
48. Travaprost (Travatan 0.004%) [package insert]. Fort Worth, TX: Alcon.